Too Early To Say FDA Issues Are Behind Lupin: Abhishek Singhal

PUBLISHED ON: July 8, 2016 | Duration: 10 min, 11 sec

   
loading..
Abhishek Singhal, associate director at Macquarie Capital Securities, says it is too early to come to a conclusion that all the FDA issues are behind Lupin. But he maintains that July 2015 inspection is all-clear is definitely a better situation for Lupin to be in rather than the entire 18 observations outstanding.
ALSO WATCH
Why SV Prasad Likes Pharma, Commodity Stocks

................................ Advertisement ................................

................................ Advertisement ................................